(8R)-Lisuride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (8R)-Lisuride
• 英文别名: 3-[(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea；3-[(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
• 化学式: C₂₀H₂₆N₄O
• 分子量: 338.453
• InChiKey: BKRGVLQUQGGVSM-RDTXWAMCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  51.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (8R)-Lisuride 生成 1,1-Diethyl-3-((6aR,9S)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)urea
  参考文献：
  名称：

  SAUER, G.

  摘要：

  DOI：
• 作为产物：
  描述：

  (+)-isolysergic acid amide 、 二乙胺 、 lead(IV) acetate 生成 (8R)-Lisuride
  参考文献：
  名称：

  SAUER, G.;HAFFER, G.

  摘要：

  DOI：

文献信息

• SAUER, G.
  作者：SAUER, G.

  DOI：——

  日期：——
• SAUER, G.;HAFFER, G.
  作者：SAUER, G.、HAFFER, G.

  DOI：——

  日期：——
• ANTI-CANCER STEMNESS DRUGS
  申请人：Development Center for Biotechnology

  公开号：US20200062738A1

  公开（公告）日：2020-02-27

  A compound for inhibiting BMI-1/MCL-1 having a structure of Formula (I), wherein the various groups are as described. A pharmaceutical composition for treating cancer includes an effective amount of a compound of Formula (I).
• [EN] COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS ET MÉTABOLIQUES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2020232255A1

  公开（公告）日：2020-11-19

  Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS.